Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group.
Matsushita Y, et al. Among authors: miyake h.
Int J Urol. 2024 May;31(5):526-533. doi: 10.1111/iju.15396. Epub 2024 Jan 19.
Int J Urol. 2024.
PMID: 38240169